KRAS inhibitors
Patent Information
- Application Number
- JP2023555534
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-13
- Filing Date
- 2022-03-14
- Publication Date
- 2025-03-25
- Estimated Expiration
- 2042-03-14
AI Technical Summary
Current attempts to develop inhibitors for the KRAS G12D mutation, a common mutation in tumors and cancers, have been hindered by the difficulty in binding to the KRAS protein due to competition with GTP in the intracellular binding pocket, particularly because the allosteric site is unknown.
The development of compounds represented by Formula (I) and (II), which include specific structural components such as aryl or heteroaryl groups, along with various substituents, to effectively inhibit KRAS G12D activity by targeting the KRAS protein.
These compounds demonstrate the ability to inhibit KRAS G12D activity, providing a potential therapeutic approach for treating cancers expressing this mutation, including pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer.